Related Experiment Video
Updated: Jan 30, 2026

Using Computer-based Image Analysis to Improve Quantification of Lung Metastasis in the 4T1 Breast Cancer Model
Published on: October 2, 2020
RLIP inhibition suppresses breast-to-lung metastasis
Jyotsana Singhal1, Shireen Chikara2, David Horne3
1Department of Medical Oncology, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA; Department of Molecular Medicine, City of Hope Comprehensive Cancer Center and National Medical Center, Duarte, CA, 91010, USA.
Abstract:
Breast tumor metastasis is a leading cause of cancer-related deaths worldwide. Breast cancer (BC) cells frequently metastasize to the lungs, where they pose a formidable therapeutic challenge. In the current study, we evaluated the anti-proliferative and anti-metastatic effects of 2'-hydroxyflavanone (2HF) and RLIP inhibition in an array of triple-negative BC cell lines and an orthotopic mouse model of breast-to-lung metastasis. Compared to control treatment, RLIP inhibition reduced in-vitro cell viability and suppressed the migratory and invasive potential of BC cells. In-vitro studies showed that 2HF treatment reduced the expression of RLIP, KRAS, pERK, pSTAT3, and pP70S6K. Further, mice orthotopically implanted with lung-seeking luciferase-expressing TMD231 cells were treated with 2HF (50 mg/kg, b.w.), RLIP antisense (RAS; 5 mg/kg, b.w.), RLIP antibody (Rab; 5 mg/kg, b.w.) or a combination of 2HF + RAS + Rab. 2HF-, RAS-, and Rab-treated mice exhibited significantly lower primary tumor weight and reduced lung metastasis compared to control mice. Mice treated with a combination of 2HF + RAS + Rab exhibited no metastasis and significantly lower tumor weight than the single agent-treated mice. Collectively, our results suggest that 2HF has potential to be combined with RLIP inhibition/depletion to more effectively suppress primary breast tumor growth and metastasis to the lungs.
Insights
This study shows that 2'-hydroxyflavanone (2HF) combined with RLIP inhibition effectively suppresses breast tumor growth and lung metastasis. This combination therapy offers a promising strategy for treating aggressive breast cancer.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Breast cancer metastasis, particularly to the lungs, is a major cause of cancer mortality.
- Triple-negative breast cancer (TNBC) presents significant therapeutic challenges due to its aggressive nature and limited treatment options.
- RLIP (Ras and-associated protein 1) is implicated in cancer cell proliferation and metastasis.
Purpose of the Study:
- To investigate the anti-proliferative and anti-metastatic effects of 2 -hydroxyflavanone (2HF) and RLIP inhibition in triple-negative breast cancer (TNBC).
- To evaluate the efficacy of combining 2HF with RLIP inhibition strategies (antisense oligonucleotide and antibody) in preclinical models.
Main Methods:
- In vitro studies using TNBC cell lines to assess cell viability, migration, and invasion.
- In vivo orthotopic mouse model of breast-to-lung metastasis using luciferase-expressing TNBC cells.
- Treatment groups included 2HF, RLIP antisense (RAS), RLIP antibody (Rab), and combination therapies.
Main Results:
- RLIP inhibition alone reduced in vitro cell viability, migration, and invasion.
- 2HF treatment decreased the expression of RLIP, KRAS, pERK, pSTAT3, and pP70S6K in vitro.
- Combined treatment with 2HF, RAS, and Rab significantly reduced primary tumor weight and completely abolished lung metastasis in mice, outperforming single-agent therapies.
Conclusions:
- 2 -hydroxyflavanone (2HF) demonstrates significant anti-proliferative and anti-metastatic properties in TNBC models.
- RLIP inhibition, via antisense or antibody, is effective in suppressing breast cancer progression and metastasis.
- The combination of 2HF with RLIP inhibition presents a potent therapeutic strategy for overcoming breast tumor growth and lung metastasis.
Related Concept Videos
Feedback Inhibition
Metastasis
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Lung Capacity
Enzyme Inhibition
Inhibition of Cdk Activity
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...

